



Drug Coverage Decision for BC PharmaCare

About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	avatrombopag
Brand name	Doptelet®
Dosage form(s)	20 mg tablet
Manufacturer	Sobi Canada Inc.
Submission type	New Submission
Indication reviewed	For the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP).
Canada’s Drug Agency (CDA-AMC) Clinical Reimbursement Reviews (CRR)	CDA-AMC recommended: Do Not Reimburse . Visit the CRR website for more details .
Drug Benefit Council (DBC)	Avatrombopag was not reviewed by the Drug Benefit Council (DBC) because it received a “do not list” recommendation from the CDA-AMC.
Drug Coverage Decision	Non-benefit
Date	November 7, 2024
Reason(s)	<p>Drug coverage decision is consistent with the Canadian Drug Expert Committee (CDEC) recommendation that Doptelet not be reimbursed for the treatment of thrombocytopenia in adults with chronic ITP.</p> <ul style="list-style-type: none"> Evidence from one clinical trial showed that after 6 months of treatment, Doptelet improved patients’ platelet counts; however, it is not known whether Doptelet can reduce bleeding occurrence, reduce the use of other therapies

- for ITP given along with Doptelet, improve symptoms, or improve health-related quality of life (HRQoL), when compared to placebo
- Patients identified a need for treatments that reduce the risk of bleeding, and improve their quality of life. However, there was not enough evidence to show that Doptelet would meet these needs.
 - Based on economic considerations and the submitted product price, avatrombopag was not cost effective and did not offer optimal value for money.
 - The pan-Canadian Pharmaceutical Alliance (pCPA) and the Ministry were not involved in negotiations with the manufacturer for this product because of the CDEC recommendation not to list.

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry by considering:

- whether the drug is safe and effective
- advice from a national group called [Canada's Drug and Health Technology Agency \(CADTH\)](#)
- what the drug costs and whether funding it provides good value to the province
- ethical considerations of covering and not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by taking into account:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.